Merck | MRK - Current Liabilities


Merck reported $28.63B in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
AbbVie USD 43.29B 3.9B Dec/2025
Abbott USD 16.5B 1.91B Dec/2025
ALKERMES USD 543.44M 69.08M Dec/2025
Amgen USD 25.49B 3.7B Dec/2025
AstraZeneca USD 30.62B 3.44B Dec/2025
Biogen USD 3.35B 59.4M Dec/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Coherus Biosciences USD 140.39M 231.91M Dec/2025
Drreddys Laboratories INR 1.76B 62.5M Dec/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Gilead Sciences USD 11.81B 485M Dec/2025
GlaxoSmithKline GBP 21.39B 57M Dec/2025
Glaxosmithkline GBP 28.82B 144.79M Dec/2025
J&J USD 54.13B 3.26B Dec/2025
Medtronic USD 9.5B 440M Dec/2025
Merck USD 28.63B 2.59B Sep/2025
Novartis USD 27.28B 4.72B Dec/2025
Novartis USD 27.28B 4.72B Dec/2025
Novo Nordisk DKK 215.66B 18.7B Dec/2025
Pacira USD 120.59M 13.51M Dec/2025
Perrigo USD 1.01B 132.4M Dec/2025
Pfizer USD 36.6B 1.13B Sep/2025
Phibro Animal Health USD 282.37M 12.23M Dec/2025
Prestige Brands USD 139.56M 4.95M Dec/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Roche Holding CHF 28B 421M Dec/2025
Sanofi EUR 28.35B 3.76B Dec/2025
Sanofi EUR 28.35B 9.32B Dec/2025
United Therapeutics USD 560.6M 14.3M Dec/2025
Zoetis USD 2.24B 428M Dec/2025